6YZ Stock Overview

An investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China. More details

6YZ fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	2/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 75.5% below our estimate of its fair value

Earnings are forecast to grow 61.72% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

Shareholders have been diluted in the past year

My Notes

Capture your thoughts, links and company narrative

New Horizon Health Limited Competitors

SYNLAB

HMSE:SYAB

€2.5b

VITA 34

XTRA:V3V

€71.8m

Fresenius Medical Care

XTRA:FME

€12.9b

RHÖN-KLINIKUM

XTRA:RHK

€923.8m

Price History & Performance

Summary of share price highs, lows and changes for New Horizon Health
Historical stock prices
Current Share Price	HK$2.26
52 Week High	HK$3.78
52 Week Low	HK$1.95
Beta	1.38
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-36.16%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-37.27%

Recent updates

Shareholder Returns

	6YZ	DE Healthcare	DE Market
7D	0%	-3.8%	-2.0%
1Y	-36.2%	15.6%	6.9%

Return vs Industry: 6YZ underperformed the German Healthcare industry which returned 0.6% over the past year.

Return vs Market: 6YZ underperformed the German Market which returned -0.9% over the past year.

Price Volatility

Is 6YZ's price volatile compared to industry and market?
6YZ volatility
6YZ Average Weekly Movement	n/a
Healthcare Industry Average Movement	4.7%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 6YZ has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 6YZ's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	1,041	Yeqing Zhu	ir.newhorizonbio.com

New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities.

New Horizon Health Limited Fundamentals Summary

How do New Horizon Health's earnings and revenue compare to its market cap?
6YZ fundamental statistics
Market cap	€936.79m
Earnings (TTM)	€14.50m
Revenue (TTM)	€176.80m

69.0x

P/E Ratio

5.7x

P/S Ratio

Is 6YZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6YZ income statement (TTM)
Revenue	CN¥1.36b
Cost of Revenue	CN¥153.40m
Gross Profit	CN¥1.21b
Other Expenses	CN¥1.10b
Earnings	CN¥111.70m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.25
Gross Margin	88.74%
Net Profit Margin	8.20%
Debt/Equity Ratio	12.7%

How did 6YZ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/01/24 05:00
End of Day Share Price	2023/10/27 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

New Horizon Health Limited is covered by 6 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	CMB International Securities Limited
Ziyi Chen	Goldman Sachs
Yinglan Shu	Haitong International Research Limited